Denali Therapeutics (DNLI) Shares Outstanding (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Shares Outstanding data on file, last reported at $158.7 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $158.7 million, up 9.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $158.7 million (up 9.23% YoY), and the FY2025 annual result was $156.2 million, up 8.29% from the prior year.
• Shares Outstanding grew to $158.7 million in Q1 2026 per DNLI's latest filing, from $156.2 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $158.7 million in Q1 2026 and troughed at $122.9 million in Q1 2022.
• A 5-year average of $140.1 million and a median of $142.5 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding advanced 1.34% in 2022, then climbed 11.53% in 2023.
• A 5-year view of Shares Outstanding shows it stood at $136.0 million in 2022, then advanced by 1.78% to $138.4 million in 2023, then increased by 4.22% to $144.2 million in 2024, then grew by 8.29% to $156.2 million in 2025, then advanced by 1.58% to $158.7 million in 2026.
• Business Quant data shows DNLI's Shares Outstanding at $158.7 million in Q1 2026, $156.2 million in Q4 2025, and $146.6 million in Q3 2025.